JAK inhibitors increase risk of cardiovascular problems and cancer, warns PRAC
European Pharmaceutical Review
NOVEMBER 1, 2022
The committee advises that Cibinqo (abrocitinib), Jyseleca (filgotinib), Olumiant (baricitinib), Rinvoq (upadacitinib) and Xeljanz (tofacitinib), used for chronic inflammatory conditions, should have limited distribution to minimise risk of serious side effects such as cardiovascular diseases, blood clots, cancer and serious infections.
Let's personalize your content